共 12 条
- [1] Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB105 - AB105Yamaguchi, YujiPeeva, ElenaShore, Ronald
- [2] Clinical efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) and patients' perception of improvement in alopecia areata: Results from the ALLEGRO Phase 2b/3 trialEXPERIMENTAL DERMATOLOGY, 2021, 30 : 20 - 20Guttman-Yassky, E.Ito, T.Jabbari, A.Mackay-Wiggan, J.Lejeune, A.Wolk, R.Wajsbrot, D.Zwillich, S. H.
- [3] Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebocontrolled trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB54 - AB54Mesinkovska, NatashaShapiro, JerryKing, Brett
- [4] Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: Results from the ALLEGRO phase 2b/3, randomized, double-blind, placebo-controlled trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106King, BrettSzepietowski, Jacek C.Farrant, Paul
- [5] Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB51 - AB51Hordinsky, Maria K.Hebert, AdelaideGooderham, Melinda
- [6] A Phase 2b dose-ranging trial of baricitinib, an oral JAM 1/JAK 2 inhibitor, in patients with moderate-to-severe psoriasis: Results from the randomized withdrawal and re-treatment periodsJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S7 - S7Papp, KimMenter, AlanRaman, ManiJanes, JonathanDisch, DamonMacias, William
- [7] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging StudyARTHRITIS & RHEUMATOLOGY, 2015, 67Kavanaugh, ArthurPonce, LuciaCseuz, ReginaReshetko, OlgaStanislavchuk, Mykola A.Greenwald, MariaVan der Aa, AnnegretVanhoutte, FredericTasset, ChantalHarrison, Pille
- [8] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging StudyARTHRITIS & RHEUMATOLOGY, 2015, 67Westhovens, R.Alten, RiekePavlova, DaceEnriquez-Sosa, FavioMazur, MinodoraGreenwald, MariaVan der Aa, AnnegretVanhoutte, FredericTasset, ChantalHarrison, Pille
- [9] Efficacy and safety of ritlecitinib (PF06651600) in patients with alopecia areata and at least 50% scalp hair loss: results from the international ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled study (NCT03732807)JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 125 - 125King, BrettZhang, XingqiGubelin, WalterSzepietowski, JacekShapiro, JerryLynde, CharlesMesinkovska, NatashaZwillich, SamuelNapatalung, LynneWajsbrot, DaliaFayyad, RanaFreyman, AmyMitra, DebanjaliPurohit, VivekSinclair, RodneyWolk, Robert
- [10] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDYANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247Kavanaugh, A.Ponce, L.Cseuz, R.Reshetko, O.Stanislavchuk, M.Greenwald, M.Van der Aa, A.Vanhoutte, F.Tasset, C.Harrison, P.